2022 World Conference on Lung Cancer (ePosters)-EP08.02-102. Feasibility and Clinical Utility of ctDNA for Detection of Sensitizing and Resistance EGFR Mutations in Patients with Non-small Cell Lung Cancer

EP08.02-102. Feasibility and Clinical Utility of ctDNA for Detection of Sensitizing and Resistance EGFR Mutations in Patients with Non-small Cell Lung Cancer

Back to course

Pdf Summary

A study was conducted to evaluate the clinical utility of liquid biopsy using crystal digital PCR (cdPCR) for detecting EGFR mutations in patients with advanced non-small cell lung cancer (NSCLC). The study found that cdPCR is a feasible and clinically useful technique for detecting sensitizing, uncommon, exon20, and resistance EGFR mutations in NSCLC patients. Blood samples were collected from patients at baseline, early time points (1 month since TKI beginning), and at progression. EGFR mutations were analyzed using cdPCR and tissue molecular profiling was done using NGS with Oncomine Focus panel. The study showed that all patients had positive EGFR ctDNA and the median progression-free survival (PFS) was 17.6 months. Clearance of EGFR cdPCR had a positive impact on prognosis, with a 6-month PFS rate of 83% in patients with complete clearance versus 50% in those with incomplete clearance. CdPCR was also associated with radiological response, with a higher percentage of positive samples in patients under response compared to those at progression. Additionally, cdPCR guided treatment with TKIs upfront in 83% of patients. The study demonstrated the feasibility and clinical utility of using cdPCR for detecting EGFR mutations in NSCLC patients, providing a non-invasive alternative to tissue molecular profiling. This liquid biopsy approach allows for molecular screening, treatment monitoring, and resistance detection. Overall, the study highlights the potential of cdPCR as a fast, sensitive, and cost-effective method for guiding treatment strategies in EGFR mutant NSCLC patients.

Asset Subtitle

Marta Garcia de Herreros

Meta Tag

Speaker Marta Garcia de Herreros

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

liquid biopsy

cdPCR

EGFR mutations

non-small cell lung cancer

NSCLC

progression-free survival

prognosis

radiological response

TKIs

molecular screening